Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 738

1.

Capturing the inherent structural dynamics of the HIV-1 envelope glycoprotein fusion peptide.

Kumar S, Sarkar A, Pugach P, Sanders RW, Moore JP, Ward AB, Wilson IA.

Nat Commun. 2019 Feb 15;10(1):763. doi: 10.1038/s41467-019-08738-5.

PMID:
30770829
2.

Stabilization of the V2 loop improves the presentation of V2 loop-associated broadly neutralizing antibody epitopes on HIV-1 envelope trimers.

de Taeye SW, Go EP, Sliepen K, Torrents de la Peña A, Badal K, Medina-Ramirez M, Lee WH, Desaire H, Wilson IA, Moore JP, Ward AB, Sanders RW.

J Biol Chem. 2019 Feb 6. pii: jbc.RA118.005396. doi: 10.1074/jbc.RA118.005396. [Epub ahead of print]

3.

Potent anti-influenza H7 human monoclonal antibody induces separation of hemagglutinin receptor-binding head domains.

Turner HL, Pallesen J, Lang S, Bangaru S, Urata S, Li S, Cottrell CA, Bowman CA, Crowe JE Jr, Wilson IA, Ward AB.

PLoS Biol. 2019 Feb 4;17(2):e3000139. doi: 10.1371/journal.pbio.3000139. eCollection 2019 Feb.

4.

Multistate design of influenza antibodies improves affinity and breadth against seasonal viruses.

Sevy AM, Wu NC, Gilchuk IM, Parrish EH, Burger S, Yousif D, Nagel MBM, Schey KL, Wilson IA, Crowe JE Jr, Meiler J.

Proc Natl Acad Sci U S A. 2019 Jan 29;116(5):1597-1602. doi: 10.1073/pnas.1806004116. Epub 2019 Jan 14.

5.

Genetic and structural insights into broad neutralization of hepatitis C virus by human VH1-69 antibodies.

Tzarum N, Giang E, Kong L, He L, Prentoe J, Augestad E, Hua Y, Castillo S, Lauer GM, Bukh J, Zhu J, Wilson IA, Law M.

Sci Adv. 2019 Jan 2;5(1):eaav1882. doi: 10.1126/sciadv.aav1882. eCollection 2019 Jan.

6.

Vaccine-Induced Protection from Homologous Tier 2 SHIV Challenge in Nonhuman Primates Depends on Serum-Neutralizing Antibody Titers.

Pauthner MG, Nkolola JP, Havenar-Daughton C, Murrell B, Reiss SM, Bastidas R, Prévost J, Nedellec R, von Bredow B, Abbink P, Cottrell CA, Kulp DW, Tokatlian T, Nogal B, Bianchi M, Li H, Lee JH, Butera ST, Evans DT, Hangartner L, Finzi A, Wilson IA, Wyatt RT, Irvine DJ, Schief WR, Ward AB, Sanders RW, Crotty S, Shaw GM, Barouch DH, Burton DR.

Immunity. 2019 Jan 15;50(1):241-252.e6. doi: 10.1016/j.immuni.2018.11.011. Epub 2018 Dec 11.

7.

Immunodominance and antigenic variation of influenza virus hemagglutinin: implications for design of universal vaccine immunogens.

Zost SJ, Wu NC, Hensley SE, Wilson IA.

J Infect Dis. 2018 Dec 9. doi: 10.1093/infdis/jiy696. [Epub ahead of print] No abstract available.

PMID:
30535315
8.

Closing and Opening Holes in the Glycan Shield of HIV-1 Envelope Glycoprotein SOSIP Trimers Can Redirect the Neutralizing Antibody Response to the Newly Unmasked Epitopes.

Ringe RP, Pugach P, Cottrell CA, LaBranche CC, Seabright GE, Ketas TJ, Ozorowski G, Kumar S, Schorcht A, van Gils MJ, Crispin M, Montefiori DC, Wilson IA, Ward AB, Sanders RW, Klasse PJ, Moore JP.

J Virol. 2019 Feb 5;93(4). pii: e01656-18. doi: 10.1128/JVI.01656-18. Print 2019 Feb 15.

PMID:
30487280
9.

HIV-1 vaccine design through minimizing envelope metastability.

He L, Kumar S, Allen JD, Huang D, Lin X, Mann CJ, Saye-Francisco KL, Copps J, Sarkar A, Blizard GS, Ozorowski G, Sok D, Crispin M, Ward AB, Nemazee D, Burton DR, Wilson IA, Zhu J.

Sci Adv. 2018 Nov 21;4(11):eaau6769. doi: 10.1126/sciadv.aau6769. eCollection 2018 Nov.

10.

Universal protection against influenza infection by a multidomain antibody to influenza hemagglutinin.

Laursen NS, Friesen RHE, Zhu X, Jongeneelen M, Blokland S, Vermond J, van Eijgen A, Tang C, van Diepen H, Obmolova G, van der Neut Kolfschoten M, Zuijdgeest D, Straetemans R, Hoffman RMB, Nieusma T, Pallesen J, Turner HL, Bernard SM, Ward AB, Luo J, Poon LLM, Tretiakova AP, Wilson JM, Limberis MP, Vogels R, Brandenburg B, Kolkman JA, Wilson IA.

Science. 2018 Nov 2;362(6414):598-602. doi: 10.1126/science.aaq0620.

PMID:
30385580
11.

Structure-Activity Relationships in Metal-Binding Pharmacophores for Influenza Endonuclease.

Credille CV, Dick BL, Morrison CN, Stokes RW, Adamek RN, Wu NC, Wilson IA, Cohen SM.

J Med Chem. 2018 Nov 21;61(22):10206-10217. doi: 10.1021/acs.jmedchem.8b01363. Epub 2018 Oct 31.

PMID:
30351002
12.

Cryo-EM structure of P. falciparum circumsporozoite protein with a vaccine-elicited antibody is stabilized by somatically mutated inter-Fab contacts.

Oyen D, Torres JL, Cottrell CA, Richter King C, Wilson IA, Ward AB.

Sci Adv. 2018 Oct 10;4(10):eaau8529. doi: 10.1126/sciadv.aau8529. eCollection 2018 Oct.

13.

Structural Basis for Recognition of a Unique Epitope by a Human Anti-tau Antibody.

Zhang H, Zhu X, Pascual G, Wadia JS, Keogh E, Hoozemans JJ, Siregar B, Inganäs H, Stoop EJM, Goudsmit J, Apetri A, Koudstaal W, Wilson IA.

Structure. 2018 Dec 4;26(12):1626-1634.e4. doi: 10.1016/j.str.2018.08.012. Epub 2018 Oct 11.

PMID:
30318466
14.

Recurring and Adaptable Binding Motifs in Broadly Neutralizing Antibodies to Influenza Virus Are Encoded on the D3-9 Segment of the Ig Gene.

Wu NC, Yamayoshi S, Ito M, Uraki R, Kawaoka Y, Wilson IA.

Cell Host Microbe. 2018 Oct 10;24(4):569-578.e4. doi: 10.1016/j.chom.2018.09.010.

PMID:
30308159
15.

Structural basis for cooperative regulation of KIX-mediated transcription pathways by the HTLV-1 HBZ activation domain.

Yang K, Stanfield RL, Martinez-Yamout MA, Dyson HJ, Wilson IA, Wright PE.

Proc Natl Acad Sci U S A. 2018 Oct 2;115(40):10040-10045. doi: 10.1073/pnas.1810397115. Epub 2018 Sep 19.

PMID:
30232260
16.

Crystal structure of the post-fusion core of the Human coronavirus 229E spike protein at 1.86 Å resolution.

Yan L, Meng B, Xiang J, Wilson IA, Yang B.

Acta Crystallogr D Struct Biol. 2018 Sep 1;74(Pt 9):841-851. doi: 10.1107/S2059798318008318. Epub 2018 Sep 3.

17.

Electron-Microscopy-Based Epitope Mapping Defines Specificities of Polyclonal Antibodies Elicited during HIV-1 BG505 Envelope Trimer Immunization.

Bianchi M, Turner HL, Nogal B, Cottrell CA, Oyen D, Pauthner M, Bastidas R, Nedellec R, McCoy LE, Wilson IA, Burton DR, Ward AB, Hangartner L.

Immunity. 2018 Aug 21;49(2):288-300.e8. doi: 10.1016/j.immuni.2018.07.009. Epub 2018 Aug 7.

18.

A multifunctional human monoclonal neutralizing antibody that targets a unique conserved epitope on influenza HA.

Bangaru S, Zhang H, Gilchuk IM, Voss TG, Irving RP, Gilchuk P, Matta P, Zhu X, Lang S, Nieusma T, Richt JA, Albrecht RA, Vanderven HA, Bombardi R, Kent SJ, Ward AB, Wilson IA, Crowe JE Jr.

Nat Commun. 2018 Jul 10;9(1):2669. doi: 10.1038/s41467-018-04704-9.

19.

The human naive B cell repertoire contains distinct subclasses for a germline-targeting HIV-1 vaccine immunogen.

Havenar-Daughton C, Sarkar A, Kulp DW, Toy L, Hu X, Deresa I, Kalyuzhniy O, Kaushik K, Upadhyay AA, Menis S, Landais E, Cao L, Diedrich JK, Kumar S, Schiffner T, Reiss SM, Seumois G, Yates JR, Paulson JC, Bosinger SE, Wilson IA, Schief WR, Crotty S.

Sci Transl Med. 2018 Jul 4;10(448). pii: eaat0381. doi: 10.1126/scitranslmed.aat0381.

20.

Immunogenetic and structural analysis of a class of HCV broadly neutralizing antibodies and their precursors.

Aleman F, Tzarum N, Kong L, Nagy K, Zhu J, Wilson IA, Law M.

Proc Natl Acad Sci U S A. 2018 Jul 17;115(29):7569-7574. doi: 10.1073/pnas.1802378115. Epub 2018 Jun 28.

21.

The Neutralizing Face of Hepatitis C Virus E2 Envelope Glycoprotein.

Tzarum N, Wilson IA, Law M.

Front Immunol. 2018 Jun 11;9:1315. doi: 10.3389/fimmu.2018.01315. eCollection 2018. Review.

22.

Co-evolution of HIV Envelope and Apex-Targeting Neutralizing Antibody Lineage Provides Benchmarks for Vaccine Design.

Rantalainen K, Berndsen ZT, Murrell S, Cao L, Omorodion O, Torres JL, Wu M, Umotoy J, Copps J, Poignard P, Landais E, Paulson JC, Wilson IA, Ward AB.

Cell Rep. 2018 Jun 12;23(11):3249-3261. doi: 10.1016/j.celrep.2018.05.046.

23.

A common antigenic motif recognized by naturally occurring human VH5-51/VL4-1 anti-tau antibodies with distinct functionalities.

Apetri A, Crespo R, Juraszek J, Pascual G, Janson R, Zhu X, Zhang H, Keogh E, Holland T, Wadia J, Verveen H, Siregar B, Mrosek M, Taggenbrock R, Ameijde J, Inganäs H, van Winsen M, Koldijk MH, Zuijdgeest D, Borgers M, Dockx K, Stoop EJM, Yu W, Brinkman-van der Linden EC, Ummenthum K, van Kolen K, Mercken M, Steinbacher S, de Marco D, Hoozemans JJ, Wilson IA, Koudstaal W, Goudsmit J.

Acta Neuropathol Commun. 2018 May 31;6(1):43. doi: 10.1186/s40478-018-0543-z.

24.

Clinical Correlations of Transcriptional Profile in Patients Infected With Avian Influenza H7N9 Virus.

Guan W, Yang Z, Wu NC, Lee HHY, Li Y, Jiang W, Shen L, Wu DC, Chen R, Zhong N, Wilson IA, Peiris M, Mok CKP.

J Infect Dis. 2018 Sep 8;218(8):1238-1248. doi: 10.1093/infdis/jiy317.

25.

Structure of a cleavage-independent HIV Env recapitulates the glycoprotein architecture of the native cleaved trimer.

Sarkar A, Bale S, Behrens AJ, Kumar S, Sharma SK, de Val N, Pallesen J, Irimia A, Diwanji DC, Stanfield RL, Ward AB, Crispin M, Wyatt RT, Wilson IA.

Nat Commun. 2018 May 16;9(1):1956. doi: 10.1038/s41467-018-04272-y.

26.

A small-molecule fragment that emulates binding of receptor and broadly neutralizing antibodies to influenza A hemagglutinin.

Kadam RU, Wilson IA.

Proc Natl Acad Sci U S A. 2018 Apr 17;115(16):4240-4245. doi: 10.1073/pnas.1801999115. Epub 2018 Apr 2.

27.

VLR Recognition of TLR5 Expands the Molecular Characterization of Protein Antigen Binding by Non-Ig-based Antibodies.

Gunn RJ, Herrin BR, Acharya S, Cooper MD, Wilson IA.

J Mol Biol. 2018 Apr 27;430(9):1350-1367. doi: 10.1016/j.jmb.2018.03.016. Epub 2018 Mar 26.

PMID:
29596914
28.

Structure and Immune Recognition of the HIV Glycan Shield.

Crispin M, Ward AB, Wilson IA.

Annu Rev Biophys. 2018 Mar 29. doi: 10.1146/annurev-biophys-060414-034156. [Epub ahead of print]

PMID:
29595997
29.

A complex epistatic network limits the mutational reversibility in the influenza hemagglutinin receptor-binding site.

Wu NC, Thompson AJ, Xie J, Lin CW, Nycholat CM, Zhu X, Lerner RA, Paulson JC, Wilson IA.

Nat Commun. 2018 Mar 28;9(1):1264. doi: 10.1038/s41467-018-03663-5.

30.

A public antibody lineage that potently inhibits malaria infection through dual binding to the circumsporozoite protein.

Tan J, Sack BK, Oyen D, Zenklusen I, Piccoli L, Barbieri S, Foglierini M, Fregni CS, Marcandalli J, Jongo S, Abdulla S, Perez L, Corradin G, Varani L, Sallusto F, Sim BKL, Hoffman SL, Kappe SHI, Daubenberger C, Wilson IA, Lanzavecchia A.

Nat Med. 2018 May;24(4):401-407. doi: 10.1038/nm.4513. Epub 2018 Mar 19.

31.

Epitopes for neutralizing antibodies induced by HIV-1 envelope glycoprotein BG505 SOSIP trimers in rabbits and macaques.

Klasse PJ, Ketas TJ, Cottrell CA, Ozorowski G, Debnath G, Camara D, Francomano E, Pugach P, Ringe RP, LaBranche CC, van Gils MJ, Bricault CA, Barouch DH, Crotty S, Silvestri G, Kasturi S, Pulendran B, Wilson IA, Montefiori DC, Sanders RW, Ward AB, Moore JP.

PLoS Pathog. 2018 Feb 23;14(2):e1006913. doi: 10.1371/journal.ppat.1006913. eCollection 2018 Feb.

32.

The Unusual Genetics and Biochemistry of Bovine Immunoglobulins.

Stanfield RL, Haakenson J, Deiss TC, Criscitiello MF, Wilson IA, Smider VV.

Adv Immunol. 2018;137:135-164. doi: 10.1016/bs.ai.2017.12.004. Epub 2018 Feb 9.

33.

Integrity of Glycosylation Processing of a Glycan-Depleted Trimeric HIV-1 Immunogen Targeting Key B-Cell Lineages.

Behrens AJ, Kumar A, Medina-Ramirez M, Cupo A, Marshall K, Cruz Portillo VM, Harvey DJ, Ozorowski G, Zitzmann N, Wilson IA, Ward AB, Struwe WB, Moore JP, Sanders RW, Crispin M.

J Proteome Res. 2018 Mar 2;17(3):987-999. doi: 10.1021/acs.jproteome.7b00639. Epub 2018 Feb 8.

PMID:
29420040
34.

Structural insights into the design of novel anti-influenza therapies.

Wu NC, Wilson IA.

Nat Struct Mol Biol. 2018 Feb;25(2):115-121. doi: 10.1038/s41594-018-0025-9. Epub 2018 Feb 2. Review.

35.

Elicitation of Neutralizing Antibodies Targeting the V2 Apex of the HIV Envelope Trimer in a Wild-Type Animal Model.

Voss JE, Andrabi R, McCoy LE, de Val N, Fuller RP, Messmer T, Su CY, Sok D, Khan SN, Garces F, Pritchard LK, Wyatt RT, Ward AB, Crispin M, Wilson IA, Burton DR.

Cell Rep. 2018 Jan 23;22(4):1103. doi: 10.1016/j.celrep.2017.10.089. Epub 2018 Jan 28. No abstract available.

36.

Harvesting Environmental Microalgal Blooms for Remediation and Resource Recovery: A Laboratory Scale Investigation with Economic and Microbial Community Impact Assessment.

Pandhal J, Choon WL, Kapoore RV, Russo DA, Hanotu J, Wilson IAG, Desai P, Bailey M, Zimmerman WJ, Ferguson AS.

Biology (Basel). 2017 Dec 29;7(1). pii: E4. doi: 10.3390/biology7010004.

37.

"Inverse Drug Discovery" Strategy To Identify Proteins That Are Targeted by Latent Electrophiles As Exemplified by Aryl Fluorosulfates.

Mortenson DE, Brighty GJ, Plate L, Bare G, Chen W, Li S, Wang H, Cravatt BF, Forli S, Powers ET, Sharpless KB, Wilson IA, Kelly JW.

J Am Chem Soc. 2018 Jan 10;140(1):200-210. doi: 10.1021/jacs.7b08366. Epub 2017 Dec 21.

38.

Probing the antigenicity of hepatitis C virus envelope glycoprotein complex by high-throughput mutagenesis.

Gopal R, Jackson K, Tzarum N, Kong L, Ettenger A, Guest J, Pfaff JM, Barnes T, Honda A, Giang E, Davidson E, Wilson IA, Doranz BJ, Law M.

PLoS Pathog. 2017 Dec 18;13(12):e1006735. doi: 10.1371/journal.ppat.1006735. eCollection 2017 Dec.

39.

Stabilization of the gp120 V3 loop through hydrophobic interactions reduces the immunodominant V3-directed non-neutralizing response to HIV-1 envelope trimers.

de Taeye SW, de la Peña AT, Vecchione A, Scutigliani E, Sliepen K, Burger JA, van der Woude P, Schorcht A, Schermer EE, van Gils MJ, LaBranche CC, Montefiori DC, Wilson IA, Moore JP, Ward AB, Sanders RW.

J Biol Chem. 2018 Feb 2;293(5):1688-1701. doi: 10.1074/jbc.RA117.000709. Epub 2017 Dec 8.

40.

Crystal structure of an anti-idiotype variable lymphocyte receptor.

Collins BC, Nakahara H, Acharya S, Cooper MD, Herrin BR, Wilson IA.

Acta Crystallogr F Struct Biol Commun. 2017 Dec 1;73(Pt 12):682-687. doi: 10.1107/S2053230X1701620X. Epub 2017 Nov 14.

41.

HIV Envelope Glycoform Heterogeneity and Localized Diversity Govern the Initiation and Maturation of a V2 Apex Broadly Neutralizing Antibody Lineage.

Landais E, Murrell B, Briney B, Murrell S, Rantalainen K, Berndsen ZT, Ramos A, Wickramasinghe L, Smith ML, Eren K, de Val N, Wu M, Cappelletti A, Umotoy J, Lie Y, Wrin T, Algate P, Chan-Hui PY, Karita E; IAVI Protocol C Investigators; IAVI African HIV Research Network, Ward AB, Wilson IA, Burton DR, Smith D, Pond SLK, Poignard P.

Immunity. 2017 Nov 21;47(5):990-1003.e9. doi: 10.1016/j.immuni.2017.11.002.

42.

cGMP production and analysis of BG505 SOSIP.664, an extensively glycosylated, trimeric HIV-1 envelope glycoprotein vaccine candidate.

Dey AK, Cupo A, Ozorowski G, Sharma VK, Behrens AJ, Go EP, Ketas TJ, Yasmeen A, Klasse PJ, Sayeed E, Desaire H, Crispin M, Wilson IA, Sanders RW, Hassell T, Ward AB, Moore JP.

Biotechnol Bioeng. 2018 Apr;115(4):885-899. doi: 10.1002/bit.26498. Epub 2017 Dec 11.

43.

Bacterially derived synthetic mimetics of mammalian oligomannose prime antibody responses that neutralize HIV infectivity.

Pantophlet R, Trattnig N, Murrell S, Lu N, Chau D, Rempel C, Wilson IA, Kosma P.

Nat Commun. 2017 Nov 17;8(1):1601. doi: 10.1038/s41467-017-01640-y.

44.

Structural basis for antibody recognition of the NANP repeats in Plasmodium falciparum circumsporozoite protein.

Oyen D, Torres JL, Wille-Reece U, Ockenhouse CF, Emerling D, Glanville J, Volkmuth W, Flores-Garcia Y, Zavala F, Ward AB, King CR, Wilson IA.

Proc Natl Acad Sci U S A. 2017 Nov 28;114(48):E10438-E10445. doi: 10.1073/pnas.1715812114. Epub 2017 Nov 14. Erratum in: Proc Natl Acad Sci U S A. 2018 Jun 11;:.

45.

A structural explanation for the low effectiveness of the seasonal influenza H3N2 vaccine.

Wu NC, Zost SJ, Thompson AJ, Oyen D, Nycholat CM, McBride R, Paulson JC, Hensley SE, Wilson IA.

PLoS Pathog. 2017 Oct 23;13(10):e1006682. doi: 10.1371/journal.ppat.1006682. eCollection 2017 Oct.

46.

Structural Insights into VLR Fine Specificity for Blood Group Carbohydrates.

Collins BC, Gunn RJ, McKitrick TR, Cummings RD, Cooper MD, Herrin BR, Wilson IA.

Structure. 2017 Nov 7;25(11):1667-1678.e4. doi: 10.1016/j.str.2017.09.003. Epub 2017 Oct 5.

47.

Elicitation of Neutralizing Antibodies Targeting the V2 Apex of the HIV Envelope Trimer in a Wild-Type Animal Model.

Voss JE, Andrabi R, McCoy LE, de Val N, Fuller RP, Messmer T, Su CY, Sok D, Khan SN, Garces F, Pritchard LK, Wyatt RT, Ward AB, Crispin M, Wilson IA, Burton DR.

Cell Rep. 2017 Oct 3;21(1):222-235. doi: 10.1016/j.celrep.2017.09.024. Erratum in: Cell Rep. 2018 Jan 23;22(4):1103.

48.

Potent peptidic fusion inhibitors of influenza virus.

Kadam RU, Juraszek J, Brandenburg B, Buyck C, Schepens WBG, Kesteleyn B, Stoops B, Vreeken RJ, Vermond J, Goutier W, Tang C, Vogels R, Friesen RHE, Goudsmit J, van Dongen MJP, Wilson IA.

Science. 2017 Oct 27;358(6362):496-502. doi: 10.1126/science.aan0516. Epub 2017 Sep 28.

49.

Massively parallel de novo protein design for targeted therapeutics.

Chevalier A, Silva DA, Rocklin GJ, Hicks DR, Vergara R, Murapa P, Bernard SM, Zhang L, Lam KH, Yao G, Bahl CD, Miyashita SI, Goreshnik I, Fuller JT, Koday MT, Jenkins CM, Colvin T, Carter L, Bohn A, Bryan CM, Fernández-Velasco DA, Stewart L, Dong M, Huang X, Jin R, Wilson IA, Fuller DH, Baker D.

Nature. 2017 Oct 5;550(7674):74-79. doi: 10.1038/nature23912. Epub 2017 Sep 27.

50.

Antibody 27F3 Broadly Targets Influenza A Group 1 and 2 Hemagglutinins through a Further Variation in VH1-69 Antibody Orientation on the HA Stem.

Lang S, Xie J, Zhu X, Wu NC, Lerner RA, Wilson IA.

Cell Rep. 2017 Sep 19;20(12):2935-2943. doi: 10.1016/j.celrep.2017.08.084.

Supplemental Content

Loading ...
Support Center